Gossamer Bio Inc. has divulged trisubstituted pyridines acting as non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of asthma, atopic dermatitis, contact dermatitis, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis and allergic rhinitis, among others.
To date, only one drug has been approved for the treatment of itch (persistent pruritus) and it only targets a small portion of the patient population. Researchers from Mallinckrodt plc have unveiled gastrin-releasing peptide receptor (GRPR) as an itch-specific receptor for nonhistaminergic itch.
Galderma Holding SA has identified metabolites of CD-14547 acting as mammalian target of rapamycin (mTOR; FRAP1) inhibitors. As such, they are reported to be useful for the treatment of acne, atopic dermatitis, actinic keratosis and psoriasis.
RHOJ, a small GTPase, could hold the key to the survival of tumor cells during cancer treatments. When epithelial cells transformed into mesenchymal cells, the Rho-related GTP-binding protein RhoJ regulated their resistance to chemotherapy. The scientists observed this mechanism in mouse models of skin squamous cell carcinoma, but their results could go beyond just one type of cancer. When the team started its experiments, which were published March 23, 2023, in Nature, “I had never heard about RHOJ before,” the lead author Cédric Blanpain told BioWorld. Blanpain is the director of the Laboratory of Stem Cells and Cancer at the Université Libre de Bruxelles (ULB).
3+2 Pharma LLC has divulged pyrazole-containing CREB-binding protein (CREBBP; CBP)/β-catenin (CTNNB1) interaction inhibitors reported to be useful for the treatment of fibrosis, cancer, aging, neurological, metabolic and dermatological disorders.
RSS
